




NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 25/08/2022

To,
The Manager,
Department of Corporate Relationship,
BSE Limited
25th P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 524414

Subject: Submission of Standalone Unaudited Financial Results in compliance with Regulation 33 of SEBI (LODR) Regulations, 2015

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Un-audited Financial Results of the Company for the Quarter ended on 30th June, 2022.
- 2) Limited Review Report on Standalone Un-audited Financial Results for the quarter ended on 30th June, 2022.

This is for your kind information and records..

Yours faithfully,
FOR NORRIS MEDICINES LIMITED


(VIMAL D. SHAH)
MANAGING DIRECTOR
DIN No. 01506655





NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
 ANKLESHWAR 393 002. (Gujarat)
 Regd. Office : Plot No. 801/P, GIDC Estate,
 ANKLESHWAR 393 002. (Gujarat)
 Telephone : (02646) 223462, 227530
 Fax : (02646) 250126
 E-mail : contact@norrispharma.com
 Website : www.norrispharma.com
 CIN : L24230GJ1990PLC086581

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2022

Sl. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Previous
		30.06.2022	31.03.2022	30.06.2021	accounting year
		Unaudited	Audited	Unaudited	Audited
1	(a) Revenue from Operations	95.31	81.94	489.33	941.92
	(b) Other Income	0.00	1.47	1.64	4.50
	Total Income From Operations (Net)	95.31	83.41	490.98	946.42
2	Expenses				
	a. Cost of Materials Consumed	35.77	49.62	109.86	356.62
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	(16.63)	(7.44)	209.93	204.04
	c. Employee Benefit Expenses	44.14	52.40	61.05	233.00
	d. Finance Costs	9.28	8.21	42.47	148.15
	e. Depreciation and Amortisation Expense	15.14	65.69	16.15	65.69
	f. Other expenditure	51.53	30.32	57.00	157.37
	Total Expenses	139.23	198.80	496.45	1164.87
3	Profit/ Loss before Tax (1-2)	-43.92	-115.39	-5.48	-218.45
4	Tax Expense				
	a: Current Tax	0	0.00	0	0.00
	b: Deferred Tax	0	107.90	0	107.90
5	Profit / Loss after Tax	-43.92	-223.29	-5.48	-326.35
6	Other Comprehensive Income				
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-43.92	-223.29	-5.48	-326.35
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.44	-2.23	-0.05	-3.26



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Notes:

- 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14.08.2021. The above results have been subjected to Audit by the Statutory Auditors of the company. The report of the Statutory Auditors is unqualified.
- 2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI circular dated 05.07.2016.
- 3) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 4) There are no exceptional/ extraordinary items during the quarter ended 30.06.2022.
- 5) The Company has been impleaded as a party in matter pertaining to the year 2001 and the Hon' ble Special Judge of the Maharashtra Protection of Interest of Depositors (in Financial Establishments) Act, 1999 and the Additional Sessions Judge City Civil and Sessions Court, Mumbai has held the company liable jointly with the erstwhile Director to pay the amount in Miscellaneous Application no. 481/2004 in Special Case no. 3 of 2003. The Company has filed an appeal against the said order dated 14.11.2019 before the High Court of Mumbai, under Criminal Appeal no. 89 of 2020.

For Norris Medicines limited

Vimal D Shah

Managing Director

Date: **.08.2020.

Place: Ankleshwar





Limited Review Report

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

We have reviewed the accompanying statement of Standalone unaudited financial results (the statement) of **NORRIS MEDICINES LIMITED** ("the company") for the quarter ended on **30th June, 2022** and for the year to date period from 1st April, 2022 to 30th June, 2022 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019 date March 29, 2019. This Statement is the responsibility of the Company's Management and has been approved by the Board of directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standards 34, "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of Companies Act 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





H.N. JADAV & CO.
CHARTERED ACCOUNTANTS

CA Harishchandra N. Jadav
B. Com, FCA, DISA (ICAI)
Mobile : 98241 25540
harishnjadav@yahoo.com
harishnjadav@gmail.com


C-24, GROUND FLOOR, SARDAR PATEL MUNICIPAL MARKET, SHAKTINATH, BHARUCH- 392 001.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards, i.e. Indian Accounting Standard ("Ind AS") and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 26/08/2022

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat

For, H. N. JADAV & Co.
Chartered Accountants


CA HARISHCHANDRA JADAV
Proprietor
M. No. 040525
(Firm Reg. No. 103801W)
UDIN: 22040525AQBZNN7427

